Intellia Therapeutics (NTLA) Competitors

Intellia Therapeutics logo
$9.78 -0.08 (-0.81%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$9.89 +0.11 (+1.12%)
As of 04:54 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

NTLA vs. BEAM, CRSP, EDIT, ORKA, and IONS

Should you buy Intellia Therapeutics stock or one of its competitors? Intellia Therapeutics's main competitors and comparable companies include Beam Therapeutics (BEAM), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), Oruka Therapeutics (ORKA), and Ionis Pharmaceuticals (IONS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Intellia Therapeutics compare to Beam Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and Intellia Therapeutics (NASDAQ:NTLA) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership.

Beam Therapeutics has higher revenue and earnings than Intellia Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Beam Therapeutics$139.74M15.29-$79.99M-$1.04N/A
Intellia Therapeutics$67.67M20.29-$412.69M-$3.35N/A

Beam Therapeutics has a net margin of -73.04% compared to Intellia Therapeutics' net margin of -805.75%. Beam Therapeutics' return on equity of -32.76% beat Intellia Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Beam Therapeutics-73.04% -32.76% -25.80%
Intellia Therapeutics -805.75%-64.74%-50.72%

Beam Therapeutics presently has a consensus price target of $47.64, suggesting a potential upside of 130.68%. Intellia Therapeutics has a consensus price target of $21.44, suggesting a potential upside of 119.27%. Given Beam Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Beam Therapeutics is more favorable than Intellia Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Beam Therapeutics
1 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.75
Intellia Therapeutics
4 Sell rating(s)
7 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.33

Beam Therapeutics has a beta of 2.23, suggesting that its share price is 123% more volatile than the broader market. Comparatively, Intellia Therapeutics has a beta of 1.83, suggesting that its share price is 83% more volatile than the broader market.

99.7% of Beam Therapeutics shares are held by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are held by institutional investors. 3.8% of Beam Therapeutics shares are held by insiders. Comparatively, 3.5% of Intellia Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Intellia Therapeutics had 1 more articles in the media than Beam Therapeutics. MarketBeat recorded 8 mentions for Intellia Therapeutics and 7 mentions for Beam Therapeutics. Beam Therapeutics' average media sentiment score of 0.73 beat Intellia Therapeutics' score of -0.08 indicating that Beam Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Beam Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Intellia Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Beam Therapeutics beats Intellia Therapeutics on 12 of the 15 factors compared between the two stocks.

How does Intellia Therapeutics compare to CRISPR Therapeutics?

Intellia Therapeutics (NASDAQ:NTLA) and CRISPR Therapeutics (NASDAQ:CRSP) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability.

Intellia Therapeutics presently has a consensus price target of $21.44, indicating a potential upside of 119.27%. CRISPR Therapeutics has a consensus price target of $72.93, indicating a potential upside of 81.64%. Given Intellia Therapeutics' higher possible upside, equities research analysts clearly believe Intellia Therapeutics is more favorable than CRISPR Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Intellia Therapeutics
4 Sell rating(s)
7 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.33
CRISPR Therapeutics
1 Sell rating(s)
6 Hold rating(s)
8 Buy rating(s)
2 Strong Buy rating(s)
2.65

Intellia Therapeutics has a net margin of -805.75% compared to CRISPR Therapeutics' net margin of -1,812.07%. CRISPR Therapeutics' return on equity of -25.59% beat Intellia Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Intellia Therapeutics-805.75% -64.74% -50.72%
CRISPR Therapeutics -1,812.07%-25.59%-17.89%

Intellia Therapeutics has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intellia Therapeutics$67.67M20.29-$412.69M-$3.35N/A
CRISPR Therapeutics$3.51M1,109.56-$581.60M-$4.74N/A

Intellia Therapeutics has a beta of 1.83, indicating that its stock price is 83% more volatile than the broader market. Comparatively, CRISPR Therapeutics has a beta of 1.92, indicating that its stock price is 92% more volatile than the broader market.

88.8% of Intellia Therapeutics shares are held by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are held by institutional investors. 3.5% of Intellia Therapeutics shares are held by insiders. Comparatively, 5.2% of CRISPR Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, CRISPR Therapeutics had 1 more articles in the media than Intellia Therapeutics. MarketBeat recorded 9 mentions for CRISPR Therapeutics and 8 mentions for Intellia Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.32 beat Intellia Therapeutics' score of -0.08 indicating that CRISPR Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Intellia Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
CRISPR Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
2 Negative mention(s)
1 Very Negative mention(s)
Neutral

Summary

CRISPR Therapeutics beats Intellia Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Intellia Therapeutics compare to Editas Medicine?

Intellia Therapeutics (NASDAQ:NTLA) and Editas Medicine (NASDAQ:EDIT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, media sentiment, valuation, institutional ownership, earnings and dividends.

Intellia Therapeutics has a beta of 1.83, indicating that its share price is 83% more volatile than the broader market. Comparatively, Editas Medicine has a beta of 2.08, indicating that its share price is 108% more volatile than the broader market.

Editas Medicine has lower revenue, but higher earnings than Intellia Therapeutics. Editas Medicine is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intellia Therapeutics$67.67M20.29-$412.69M-$3.35N/A
Editas Medicine$40.52M6.97-$160.06M-$0.62N/A

88.8% of Intellia Therapeutics shares are owned by institutional investors. Comparatively, 71.9% of Editas Medicine shares are owned by institutional investors. 3.5% of Intellia Therapeutics shares are owned by insiders. Comparatively, 3.1% of Editas Medicine shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Editas Medicine has a net margin of -144.95% compared to Intellia Therapeutics' net margin of -805.75%. Intellia Therapeutics' return on equity of -64.74% beat Editas Medicine's return on equity.

Company Net Margins Return on Equity Return on Assets
Intellia Therapeutics-805.75% -64.74% -50.72%
Editas Medicine -144.95%-130.43%-36.45%

Intellia Therapeutics currently has a consensus price target of $21.44, suggesting a potential upside of 119.27%. Editas Medicine has a consensus price target of $5.83, suggesting a potential upside of 218.76%. Given Editas Medicine's stronger consensus rating and higher possible upside, analysts clearly believe Editas Medicine is more favorable than Intellia Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Intellia Therapeutics
4 Sell rating(s)
7 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.33
Editas Medicine
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.71

In the previous week, Editas Medicine had 3 more articles in the media than Intellia Therapeutics. MarketBeat recorded 11 mentions for Editas Medicine and 8 mentions for Intellia Therapeutics. Editas Medicine's average media sentiment score of 0.34 beat Intellia Therapeutics' score of -0.08 indicating that Editas Medicine is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Intellia Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Editas Medicine
4 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Editas Medicine beats Intellia Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Intellia Therapeutics compare to Oruka Therapeutics?

Intellia Therapeutics (NASDAQ:NTLA) and Oruka Therapeutics (NASDAQ:ORKA) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.

Oruka Therapeutics has lower revenue, but higher earnings than Intellia Therapeutics. Oruka Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intellia Therapeutics$67.67M20.29-$412.69M-$3.35N/A
Oruka TherapeuticsN/AN/A-$105.43M-$2.11N/A

Intellia Therapeutics has a beta of 1.83, suggesting that its stock price is 83% more volatile than the broader market. Comparatively, Oruka Therapeutics has a beta of -0.34, suggesting that its stock price is 134% less volatile than the broader market.

88.8% of Intellia Therapeutics shares are owned by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are owned by institutional investors. 3.5% of Intellia Therapeutics shares are owned by company insiders. Comparatively, 23.5% of Oruka Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Oruka Therapeutics had 16 more articles in the media than Intellia Therapeutics. MarketBeat recorded 24 mentions for Oruka Therapeutics and 8 mentions for Intellia Therapeutics. Oruka Therapeutics' average media sentiment score of 0.06 beat Intellia Therapeutics' score of -0.08 indicating that Oruka Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Intellia Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Oruka Therapeutics
6 Very Positive mention(s)
2 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Oruka Therapeutics has a net margin of 0.00% compared to Intellia Therapeutics' net margin of -805.75%. Oruka Therapeutics' return on equity of -19.34% beat Intellia Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Intellia Therapeutics-805.75% -64.74% -50.72%
Oruka Therapeutics N/A -19.34%-18.74%

Intellia Therapeutics presently has a consensus target price of $21.44, suggesting a potential upside of 119.27%. Oruka Therapeutics has a consensus target price of $141.80, suggesting a potential upside of 47.22%. Given Intellia Therapeutics' higher probable upside, analysts plainly believe Intellia Therapeutics is more favorable than Oruka Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Intellia Therapeutics
4 Sell rating(s)
7 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.33
Oruka Therapeutics
1 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.80

Summary

Oruka Therapeutics beats Intellia Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Intellia Therapeutics compare to Ionis Pharmaceuticals?

Ionis Pharmaceuticals (NASDAQ:IONS) and Intellia Therapeutics (NASDAQ:NTLA) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

In the previous week, Ionis Pharmaceuticals had 18 more articles in the media than Intellia Therapeutics. MarketBeat recorded 26 mentions for Ionis Pharmaceuticals and 8 mentions for Intellia Therapeutics. Ionis Pharmaceuticals' average media sentiment score of 0.22 beat Intellia Therapeutics' score of -0.08 indicating that Ionis Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ionis Pharmaceuticals
6 Very Positive mention(s)
4 Positive mention(s)
9 Neutral mention(s)
6 Negative mention(s)
0 Very Negative mention(s)
Neutral
Intellia Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Ionis Pharmaceuticals has higher revenue and earnings than Intellia Therapeutics. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ionis Pharmaceuticals$944M4.76-$381.39M-$3.32N/A
Intellia Therapeutics$67.67M20.29-$412.69M-$3.35N/A

Ionis Pharmaceuticals currently has a consensus target price of $75.71, indicating a potential upside of 180.84%. Intellia Therapeutics has a consensus target price of $21.44, indicating a potential upside of 119.27%. Given Ionis Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Ionis Pharmaceuticals is more favorable than Intellia Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ionis Pharmaceuticals
1 Sell rating(s)
3 Hold rating(s)
19 Buy rating(s)
0 Strong Buy rating(s)
2.78
Intellia Therapeutics
4 Sell rating(s)
7 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.33

Ionis Pharmaceuticals has a net margin of -56.98% compared to Intellia Therapeutics' net margin of -805.75%. Intellia Therapeutics' return on equity of -64.74% beat Ionis Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Ionis Pharmaceuticals-56.98% -120.62% -16.99%
Intellia Therapeutics -805.75%-64.74%-50.72%

93.9% of Ionis Pharmaceuticals shares are held by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are held by institutional investors. 1.8% of Ionis Pharmaceuticals shares are held by insiders. Comparatively, 3.5% of Intellia Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Ionis Pharmaceuticals has a beta of 0.43, indicating that its stock price is 57% less volatile than the broader market. Comparatively, Intellia Therapeutics has a beta of 1.83, indicating that its stock price is 83% more volatile than the broader market.

Summary

Ionis Pharmaceuticals beats Intellia Therapeutics on 11 of the 16 factors compared between the two stocks.

Get Intellia Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NTLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NTLA vs. The Competition

MetricIntellia TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1.38B$4.06B$7.83B$11.74B
Dividend YieldN/A3.63%2.47%4.47%
P/E RatioN/A27.9434.0027.43
Price / Sales20.2915.778.485.70
Price / CashN/A22.9521.0121.90
Price / Book2.244.184.463.72
Net Income-$412.69M-$24.15M$3.52B$393.10M
7 Day Performance-14.29%-7.81%-5.94%-5.76%
1 Month Performance-14.36%-6.00%-4.59%-7.14%
1 Year Performance15.47%-8.10%-1.93%-7.46%

Intellia Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NTLA
Intellia Therapeutics
2.5147 of 5 stars
$9.78
-0.8%
$21.44
+119.3%
+15.3%$1.38B$67.67MN/A377
BEAM
Beam Therapeutics
2.855 of 5 stars
$27.02
+2.3%
$47.36
+75.3%
-6.2%$2.88B$139.74MN/A540
CRSP
CRISPR Therapeutics
2.6387 of 5 stars
$50.04
-0.1%
$69.69
+39.3%
-27.4%$5.02B$3.51MN/A393
EDIT
Editas Medicine
2.1403 of 5 stars
$2.75
+7.0%
$5.83
+112.1%
-29.1%$417.74M$40.52MN/A87
ORKA
Oruka Therapeutics
2.7224 of 5 stars
$104.56
+1.7%
$133.00
+27.2%
+241.2%$6.71BN/AN/A68

Related Companies and Tools


This page (NASDAQ:NTLA) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners